Tag Archives: DESTINY-Gastric01 trial

Rare disease: Enhertu of AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release